KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Change in Receivables (2016 - 2025)

Fulgent Genetics' Change in Receivables history spans 10 years, with the latest figure at $15.4 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 15.4% year-over-year to $15.4 million; the TTM value through Dec 2025 reached $23.3 million, up 42.62%, while the annual FY2025 figure was $23.3 million, 42.62% up from the prior year.
  • Change in Receivables for Q4 2025 was $15.4 million at Fulgent Genetics, up from -$4.9 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $34.6 million in Q1 2021 and bottomed at -$67.1 million in Q2 2021.
  • The 5-year median for Change in Receivables is $2.2 million (2024), against an average of -$3.7 million.
  • The largest YoY upside for Change in Receivables was 33364.42% in 2021 against a maximum downside of 989.21% in 2021.
  • A 5-year view of Change in Receivables shows it stood at $22.7 million in 2021, then crashed by 295.67% to -$44.4 million in 2022, then surged by 111.72% to $5.2 million in 2023, then skyrocketed by 155.86% to $13.3 million in 2024, then increased by 15.4% to $15.4 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Change in Receivables are $15.4 million (Q4 2025), -$4.9 million (Q3 2025), and $8.3 million (Q2 2025).